GLP-3 (Reta) 20mg GLP-3 (Retatrutide) is a multi-pathway receptor agonist widely utilized in preclinical research involving metabolic regulation, incretin signaling, glucagon-associated pathways, and energy balance-related biochemical processes
2a, b), the inhibitory effect of GLP-1(736) and (936) on glucagon secretion persisted (Fig
Mounjaro is used for the management of type 2 diabetes, while Zepbound is indicated for weight loss and sleep apnea
The FDA has approved multiple GLP-1 agents for chronic weight management in adults with obesity or overweight status with weight-related comorbidities
Gastrointestinal eventsnausea, vomiting, diarrhea, constipation, abdominal painare the most frequently reported adverse reactions and the leading cause of treatment discontinuation